ClinicalTrials.gg
CompletedNCT02864082Updated Sep 29, 2021Results posted

A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis

A Phase 2 interventional study of PAT-001, 0.1% and PAT-001, 0.2% in Congenital Ichthyosis, sponsored by Patagonia Pharmaceuticals, LLC. Completed at 5 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-09-29.

Sponsored by Patagonia Pharmaceuticals, LLC · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

Congenital ichthyosis (CI) is a large, heterogeneous family of inherited skin disorders of cornification resulting from an abnormality of skin keratinization, such as scaling and thickening of the skin. Treatment options include keratolytic agents, which can abruptly lead to extensive shedding or peeling of scales. PAT-001 primarily acts as a keratolytic agent; thus, making it a potential drug candidate for the treatment of skin disorders associated with hyperkeratinization, such as CI. The current study intends to evaluate the safety and tolerability of PAT-001 in patients with CI of either the Lamellar or X-Linked subtypes.

Read the detailed description

The management of CI is a life-long endeavor, which remains largely symptomatic (i.e., emollients with or without keratolytics agents) and commonly focused on reducing scaling and/or skin lubrication with both systemic and topical treatments. A first-line therapy includes hydration and lubrication accomplished by creams and ointments containing low concentrations of salt, urea, or glycerol, which increase the water-binding capacity of the horny layer. Addition of keratolytics agents are used to decrease corneocyte cohesiveness, to promote desquamation, and to dissolve keratins and lipids (e.g., α-hydroxy acids, salicylic acid, high dose urea, propylene glycol, N-acetylcysteine, and retinoids). Systemic retinoid treatment is reserved for those patients refractory to topical agents because of long-term adverse effects and teratogenicity.

This is a two part, Phase 2, multicenter, proof-of-concept (POC) study of the safety and tolerability of PAT-001 for the treatment of Congenital ichthyosis (CI) in patients ages 12 years of age and older. Part 1 will be a double-blind, randomized, vehicle controlled, bilateral comparison of two treatments (PAT-001 [0.1% or 0.2%] vs. vehicle) for eight (8) weeks.

Part 2 will be a double-blind, active only treatment comparison of the two PAT-001 concentrations (0.1% or 0.2%) for an additional four (4) weeks. Subjects will have the option to participate in the pharmacokinetics (PK) portion of the study.

02

Conditions studied

  • Congenital Ichthyosis

Keywords

  • X-linked, lamellar
03

In context

Lead sponsor

This is the only study on the registry with Patagonia Pharmaceuticals, LLC as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of either sex aged 12 years or older.
  • Females of should use appropriate . Women of childbearing potential must have a negative pregnancy test at screening and baseline visits.
  • Patient and legal representative(s), if applicable, has provided written .
  • Patient has congenital ichthyosis of either lamellar or X-Linked subtype.
  • Patient has two contralateral comparable Treatment Areas (e.g., each arm is affected and treatments areas can be applied equally).
  • Patient is, except for their ichthyosis, in good general health.

Exclusion criteria

Exclusion Criteria:

  • Patient is pregnant or breast feeding, or is planning to become pregnant during the study.
  • Patient has inflammatory skin disease unrelated to ichthyosis.
  • Patient is currently using concomitant retinoid therapy, within two weeks (topical) or 12 weeks (oral) of Visit 2/Baseline.
  • Patient is currently taking concomitant drugs, including systemic , within two weeks of Visit 2/Baseline.
  • Patient is currently enrolled in an drug or device study.
  • Patient has used an investigational drug or investigational device treatment within 30 days prior to Visit 2/Baseline.
  • Patient is unable to communicate or cooperate with the investigator due to language problems, impaired cerebral function, or physical limitations.
  • Patient is known to be noncompliant or is unlikely to comply with the requirements of the study protocol (e.g., due to alcoholism, drug dependency, mental incapacity) in the opinion of the investigator.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    PAT-001 0.1%

    Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.1% (e.g., left side) and Vehicle, 0.0% (e.g., right side). This comparison lasts from Weeks 0-8 Part 2: Patients will apply only PAT-001, 0.1% to both Treatment Areas from Weeks 8-12.

    Drug: PAT-001, 0.1%

  • Experimental
    PAT-001 0.2%

    Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.2% (e.g., left side) and Vehicle, 0.0% (e.g., right side). This comparison lasts from Weeks 0-8 Part 2: Patients will apply PAT-001, 0.2% to both Treatment Areas.

    Drug: PAT-001, 0.2%

  • Placebo comparator
    Vehicle for PAT-001 0.1% arm

    Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.1% (e.g., left side) and Vehicle, 0.0% (e.g., right side). The application of vehicle only lasts from Weeks 0-8.

    Drug: Vehicle for PAT-001 0.1%

  • Placebo comparator
    Vehicle for PAT-001 0.2% arm

    Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.2% (e.g., left side) and Vehicle, 0.0% (e.g., right side). The application of vehicle only lasts from Weeks 0-8.

    Drug: Vehicle for PAT-001 0.2%

Interventions

  • PAT-001 is a topical ointment. PAT-001, 0.1% contains 0.1% of active drug.

    Also known as: PAT-001

  • PAT-001 is a topical ointment. PAT-001, 0.2% contains 0.2% of active drug.

    Also known as: PAT-001

  • DrugVehicle for PAT-001 0.1%

    Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001 0.1%.

    Also known as: Vehicle

  • DrugVehicle for PAT-001 0.2%

    Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001 0.2%.

    Also known as: Vehicle

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) in Part 1 of Trial (Weeks 0-8)

    The number of participants with AEs will be assessed by the investigator and the incidence (severity and causality) of any local and systemic AEs will be reported.

    Time frame: Day 0 through Day 57 (Weeks 0-8)

  2. Incidence of Local Skin Reactions (LSRs) in Participants Treated With PAT-001 0.1%, 0.2% and/or Vehicle

    LSRs including burning/stinging, pain, and pruritus (itch) will be assessed in each Treatment Area using a four-point ordinal scale where 0=none, 1=mild, 2=moderate, and 3=severe (based on the investigator's evaluation of the skin reaction) at each clinic visit to allow a comparison between Treatment Groups and Test Articles. Only LSRs that require medical intervention (e.g., prescription medication) or require withholding or reduction in dosing frequency of the test articles will be documented in this LSR Table. Any LSRs that are not listed here will be recorded as AEs.

    Time frame: Up to Day 84 (Weeks 0-12)

Secondary outcomes

  1. Number of Participants Achieving Improvement to State of Clear, Almost Clear or Mild in the Investigator's Global Assessment (IGA) Using a Five-point Scale at Day 57 (Part 1)

    Overall severity of ichthyosis will be graded using a five-point scale Investigator Global Assessment (IGA) based upon a 5 point scale going from 0=clear., 1=almost clear, 2=mild, 3=moderate to 4=severe. Scoring is based upon investigator evaluation. This is a static morphological scale that refers to a point in time and not a comparison to Baseline.

    Time frame: Up to Day 57

  2. Number of Participants Achieving an Improvement of at Least 1 Point Score in the Individual Clinical Signs/Symptoms of Erythema, Scaling, Fissuring and Papulation/Lichenification Using a Five-point Scale

    Overall severity of erythema (redness), scaling , fissuring (cracks in skin), and papulation/lichenification (skin thickening, increased pigmentation and/or exaggerated skin lines, formation of papules) will be graded using a five-point scale from 0=clear, 1=almost clear, 2=mild, 3=moderate to 4=severe. This is a static morphological scale that refers to a point in time and not a comparison to Baseline. This scoring is based upon investigator discretion.

    Time frame: Up to Day 57 (Weeks 0-8)

Other outcomes

  1. Pharmacokinetics of PAT-001 0.1% and 0.2% at Different Timepoints

    Serum concentrations for PAT-001 0.1% and PAT-001 0.2% looking at blood levels obtained at timepoints outlined

    Time frame: Day 1 (0,1, 2, 3, and 4 hours post Dose)

07

Results

Posted Sep 2, 2021
Limitations and caveats
Data should be interpreted with caution due to small sample sizes

Participant flow

Recruitment: March 8, 2017-February 13, 2018. Recruited at 5 clinics in United States associated with US Universities by practicing dermatologists

Participant flow — Overall Study
MilestoneGroup 1 PAT-001 0.1% and VehicleGroup 2 PAT-001 0.2% and Vehicle
Started109
Completed75
Not completed34
Withdrew: Adverse event11
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject22

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs) in Part 1 of Trial (Weeks 0-8)

The number of participants with AEs will be assessed by the investigator and the incidence (severity and causality) of any local and systemic AEs will be reported.

Time frame:
Day 0 through Day 57 (Weeks 0-8)
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs) in Part 1 of Trial (Weeks 0-8)
participantsGroup 1 PAT-001 0.1%Group 2 PAT-001 0.2%Group 1 VehicleGroup 2 Vehicle
Number of Subjects with TEAE7755
Number of Treatment Emergent Adverse Events (TEAE) within treatment area4533
Number of Deaths due to TEAE0000
Number of Serious TEAE0100
Number of Patients who Discontinued in the trial due to TEAE1100
Number of Patients with Severe TEAE1100
Number of Patients with Moderate TEAE3322
Number of Patients with Mild TEAE4633
Number of Patients Where the TEAE was Considered Definitely Related to Treatment1100
Number of Patients where the TEAE was Considered Probably Related to Treatment1000
Number of Patients Where the TEAE was Considered Possibly Related to Treatment1411
Number of Patients Where the TEAE was Considered Not Related to Treatment1544
PrimaryIncidence of Local Skin Reactions (LSRs) in Participants Treated With PAT-001 0.1%, 0.2% and/or Vehicle

LSRs including burning/stinging, pain, and pruritus (itch) will be assessed in each Treatment Area using a four-point ordinal scale where 0=none, 1=mild, 2=moderate, and 3=severe (based on the investigator's evaluation of the skin reaction) at each clinic visit to allow a comparison between Treatment Groups and Test Articles. Only LSRs that require medical intervention (e.g., prescription medication) or require withholding or reduction in dosing frequency of the test articles will be documented in this LSR Table. Any LSRs that are not listed here will be recorded as AEs.

Time frame:
Up to Day 84 (Weeks 0-12)
Reported as:
Number · participants
Incidence of Local Skin Reactions (LSRs) in Participants Treated With PAT-001 0.1%, 0.2% and/or Vehicle
participantsGroup 1 PAT-001 0.1%Group 1 VehicleGroup 2 PAT-001 0.2%Group 2 Vehicle
Application site pruritis (severe)1000
Application site irritation (mild)3200
Application site dermatitis (moderate)0010
Application site rash (mild)1001
Application site reaction (mild)0010
Application site pain (moderate)1000
Application site Pruritis (moderate)1100
Application site Pruritis (mild)1100
Application site Dermatitis (mild)0012
SecondaryNumber of Participants Achieving Improvement to State of Clear, Almost Clear or Mild in the Investigator's Global Assessment (IGA) Using a Five-point Scale at Day 57 (Part 1)

Overall severity of ichthyosis will be graded using a five-point scale Investigator Global Assessment (IGA) based upon a 5 point scale going from 0=clear., 1=almost clear, 2=mild, 3=moderate to 4=severe. Scoring is based upon investigator evaluation. This is a static morphological scale that refers to a point in time and not a comparison to Baseline.

Time frame:
Up to Day 57
Reported as:
Count of participants · Participants
Number of Participants Achieving Improvement to State of Clear, Almost Clear or Mild in the Investigator's Global Assessment (IGA) Using a Five-point Scale at Day 57 (Part 1)
ParticipantsGroup 1 PAT-001 0.1%Group 2 PAT-001 0.2%Group 1 VehicleGroup 2 Vehicle
Number of Participants Achieving Improvement to State of Clear, Almost Clear or Mild in the Investigator's Global Assessment (IGA) Using a Five-point Scale at Day 57 (Part 1)9867
SecondaryNumber of Participants Achieving an Improvement of at Least 1 Point Score in the Individual Clinical Signs/Symptoms of Erythema, Scaling, Fissuring and Papulation/Lichenification Using a Five-point Scale

Overall severity of erythema (redness), scaling , fissuring (cracks in skin), and papulation/lichenification (skin thickening, increased pigmentation and/or exaggerated skin lines, formation of papules) will be graded using a five-point scale from 0=clear, 1=almost clear, 2=mild, 3=moderate to 4=severe. This is a static morphological scale that refers to a point in time and not a comparison to Baseline. This scoring is based upon investigator discretion.

Time frame:
Up to Day 57 (Weeks 0-8)
Reported as:
Number · participants
Number of Participants Achieving an Improvement of at Least 1 Point Score in the Individual Clinical Signs/Symptoms of Erythema, Scaling, Fissuring and Papulation/Lichenification Using a Five-point Scale
participantsGroup 1 PAT-001 0.1%Group 2 PAT-001 0.2%Group 1 VehicleGroup 2 Vehicle
Scaling9678
Fissuring6656
Papulation/lichenification9667
Erythema5546
Other pre-specifiedPharmacokinetics of PAT-001 0.1% and 0.2% at Different Timepoints

Serum concentrations for PAT-001 0.1% and PAT-001 0.2% looking at blood levels obtained at timepoints outlined

Time frame:
Day 1 (0,1, 2, 3, and 4 hours post Dose)
Reported as:
Mean · ng/mL
Pharmacokinetics of PAT-001 0.1% and 0.2% at Different Timepoints
ng/mLGroup 1Group 2 (Part 1)
Pre-Dose1.495 ± 0.67182.48 ± 1.795
1 Hour1.5 ± 0.65052.227 ± 1.3725
2 Hours1.425 ± 0.53032.12 ± 1.2257
3 Hours1.37 ± 0.2972.063 ± 1.5332
4 Hours1.375 ± 0.07781.453 ± 0.3625

Adverse events

Collected over 84 Days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1 PAT-001 0.1%0/10 (0%)0/10 (0%)7/10 (70%)
Group 2 PAT-001 0.2%0/9 (0%)1/9 (11.1%)7/9 (77.8%)
Group 1 Vehicle0/10 (0%)0/10 (0%)2/10 (20%)
Group 2 Vehicle0/9 (0%)0/9 (0%)1/9 (11.1%)
Most frequent serious events
Most frequent serious events
EventGroup 1 PAT-001 0.1%Group 2 PAT-001 0.2%Group 1 VehicleGroup 2 Vehicle
C. difficile colitisInfections and infestations0/101/90/100/9
Novavirus gastroenteritisInfections and infestations0/101/90/100/9
mental status changesPsychiatric disorders0/101/90/100/9
Most frequent other events
Showing 10 of 18
Most frequent other events
EventGroup 1 PAT-001 0.1%Group 2 PAT-001 0.2%Group 1 VehicleGroup 2 Vehicle
Application site pruritisGeneral disorders3/100/92/101/9
Upper Respiratory Tract InfectionInfections and infestations0/102/90/100/9
Arthropod biteInjury, poisoning and procedural complications2/100/90/100/9
Application site dermatitisSkin and subcutaneous tissue disorders2/100/90/100/9
C. difficile colitisInfections and infestations0/101/90/100/9
Blood triglycerides increasedInvestigations0/101/90/100/9
Mental status changesPsychiatric disorders0/101/90/100/9
Gastroenteritis novovirusInfections and infestations0/101/90/100/9
Tooth infectionInfections and infestations0/101/90/100/9
ContusionInjury, poisoning and procedural complications0/101/90/100/9

Baseline characteristics

Age, Continuous
Age, Continuous(years)Group 1 PAT-001 0.1% and VehicleGroup 2 PAT-001 0.2% and VehicleTotal
Mean37.5 ± 20.347.2 ± 18.442 ± 19.3
Sex: Female, Male
Sex: Female, Male(Participants)Group 1 PAT-001 0.1% and VehicleGroup 2 PAT-001 0.2% and VehicleTotal
Female549
Male5510
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1 PAT-001 0.1% and VehicleGroup 2 PAT-001 0.2% and VehicleTotal
Hispanic or Latino000
Not Hispanic or Latino10919
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Group 1 PAT-001 0.1% and VehicleGroup 2 PAT-001 0.2% and VehicleTotal
United States10919
BMI
BMI(kg/m^2)Group 1 PAT-001 0.1% and VehicleGroup 2 PAT-001 0.2% and VehicleTotal
Median28.8 (19 to 33.9)26.4 (18 to 41.2)27.7 (18 to 41.2)
08

Study locations

5 sites
  • TCR Medical Corporation
    San Diego, California 92123, United States
  • Yale Center for Clinical Investigation
    New Haven, Connecticut 06519, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Paddington Testing Co., Inc
    Philadelphia, Pennsylvania 19103, United States
  • Texas Dermatology and Laser Specialists
    San Antonio, Texas 78218, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Feb 2018, 11 months.

Results were first posted in Sep 2021, 3 years 6 months after primary completion. A results delay was requested in Jun 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2016
First posted
Aug 11, 2016
StartActual
Mar 8, 2017
Primary completionActual
Feb 13, 2018
CompletionActual
Dec 4, 2018
Results delay requested
Jun 17, 2019
Results first posted
Sep 2, 2021
Last update
Sep 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02864082
Lead sponsor
Patagonia Pharmaceuticals, LLC
Responsible party
Sponsor
First posted
Aug 11, 2016
Start date
Mar 8, 2017
Primary completion
Feb 13, 2018
Completion
Dec 4, 2018
Results posted
Sep 2, 2021
Last update
Sep 29, 2021

Study contacts

Zachary Rome, BS
study director · Sponsor GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Isotretinoin

Start the discussion